Tessa Therapeutics Autologous and Allogeneic Cell Therapy Data to be Featured at the 17th International Conference on Malignant Lymphoma, Lugano

On May 30, 2023 Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, reported two presentations featuring clinical data from the company’s autologous CD30 CAR-T therapy TT11 and off-the-shelf CD30 CAR EBVST therapy (TT11X) will be featured at the 17th International Conference on Malignant Lymphoma taking place from June 13-17, 2023, at Lugano, Switzerland (Press release, Tessa Therapeutics, MAY 30, 2023, View Source [SID1234632222]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

TT11, is Tessa’s autologous CD30.CAR-T therapy currently being investigated in combination with Nivolumab in a Phase 1B (ACTION) study targeting R/R classical Hodgkin Lymphoma (cHL) patients. A poster providing first peak into data from this combination study will be presented at ICML, 2023.

TT11X, Tessa’s allogeneic "off-the-shelf" cell therapy, is based on Tessa’s proprietary CD30.CAR-modified Epstein-Barr virus-specific T-cell (EBVST) platform. An abstract highlighting updated data from the ongoing Phase 1 study of TT11X (BESTA) in CD30-positive lymphomas will be featured in an oral podium presentation at ICML, 2023.

Details of the two presentations are as follows:

17th International Conference on Malignant Lymphoma, Lugano

Abstract Number: 388 (Poster)
Abstract Title: Combined autologous CD30.CAR-T cells and nivolumab in patients with relapsed or refractory classical Hodgkin Lymphoma after failure of frontline therapy (ACTION study)
Session Date: Friday, 16 June (even-numbered posters)
Time: 12:30 to 13:00

Abstract Number: 47 (Podium)
Abstract Title: Off-the-shelf CD30.CAR-modified Epstein-Barr Virus-specific T cells (CD30.CAR EBVSTs) provide a safe and effective therapy for patients with Hodgkin lymphoma (HL)
Session: SESSION 7 – NEW CAR-T CELL APPROACHES
Session Date: Thursday, 15 June
Time: 15:30 to 16:45